Ada göre bir ilaç arayın

Torsemide Intravenous ve Ototoksisite

Torsemide Intravenous ilacının Ototoksisite hastalığı ile etkileşiminin güvenlik kontrolünün sonucu.

Kontrolün sonucu:

Torsemide Intravenous <> Ototoksisite

Güncellik: 23.07.2019 Eleştirmen: MD PHD P.M. Shkutko, in

Drugs.com, Rxlist.com, Webmd.com, Medscape.com gibi yetkili kaynaklara dayalı kontrolün sonucunda bu ilacın bu komorbid hastalık ile etkileşmesi halinde zarar verebilen veya olumsuz etkisini artırabilen kontrendikasyonlar veya yan etkiler bulundu.

Tüketici:

Kulak çınlaması ve işitme kaybı, hem de geri döndürülebilir ve kalıcı, loop diüretik kullanımı ile bildirilmiştir. Ototoksik etkiler genellikle hızlı damar içi veya kas içi enjeksiyon diğer ototoksik ajanların ve/veya birlikte kullanımı (yani birkaç kez önerilen dozda), ağır böbrek yetmezliği, olağandışı yüksek dozlarda ile ilişkili olmuştur. Loop diüretikler ile tedavi tanınması gecikme veya bir ilaca bağlı ototoksik etkisi tanısı şaşkın olabilir beri temkinli hazır vestibüler ve/veya işitme bozukluğu olan hastalarda uygulanmalıdır. Yüksek doz parenteral tedavi kontrollü infüzyon olarak uygulanmalıdır.

Kaynaklar

Ballantyne J "Ototoxicity: a clinical review." Audiology 12 (1973): 325-36
Beauchamp GD, Crouch TC "Deafness. Review of intravenous ethacrynic acid." J Kans Med Soc 76 (1975): 166-8,180
Hybels RL "Drug toxicity of the inner ear." Med Clin North Am 63 (1979): 309-19
Schwartz FD, Pillay VK, Kark RM "Ethacrynic acid: its usefulness and untoward effects." Am Heart J 79 (1970): 427-8
Schneider WJ, Becker EL "Acute transient hearing loss after ethacrynic acid therapy." Arch Intern Med 117 (1966): 715-7
Lloyd-Mostyn R, Lord I "Ototoxicity of intravenous furosemide." Lancet 2 (1971): 1156
Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995): 1771-80
Marlowe FI "Ototoxic agents." Otolaryngol Clin North Am 11 (1978): 791-800
Rybak LP "Ototoxicity of ethacrynic acid (a persistent clinical problem)." J Laryngol Otol 102 (1988): 518-20
Ng PS, Conley CE, Ing TS "Deafness after ethacrynic acid." Lancet 1 (1969): 673-4
Gomolin IH, Garschick E "Ethacrynic acid-induced deafness accompanied by nystagmus." N Engl J Med 303 (1980): 702
Chaffee WG Jr "Hazards of ethacrynic acid." JAMA 212 (1970): 159
Sheffield PA, Turner JS Jr "Ototoxic drugs: a review of clinical aspects, histopathologic changes and mechanisms of action." South Med J 64 (1971): 359-63
David D, Hitzig P "Diuretics and ototoxicity." N Engl J Med 284 (1971): 1328
Quick CA, Hoppe W "Permanent deafness associated with furosemide administration." Ann Otol Rhinol Laryngol 84 (1975): 94-101
Schwartz G "Ototoxicity induced by furosemide." N Engl J Med 282 (1970): 1413
Matz GJ "The ototoxic effects of ethacrynic acid in man and animals." Laryngoscope 86 (1976): 1065-86
Dunn CJ, Fitton A, Brogden RN "Torasemide: an update of its pharmacological properties and therapeutic efficacy." Drugs 49 (1995): 121-42
Ajodhia JM, Dix MR "Drug-induced deafness and its treatment." Practitioner 216 (1976): 561-70
"Product Information. Bumex (bumetanide)." Roche Laboratories, Nutley, NJ.
Meriwether WD, Mangi RJ, Serpick AA "Deafness following standard intravenous dose of ethacrynic acid." JAMA 216 (1971): 795-8
"Product Information. Edecrin (ethacrynic acid)." Merck & Co, Inc, West Point, PA.
Heidland A, Wigand N "Influence of high doses of furosemide on hearing of uremic patients." Klin Wochenschr 48 (1970): 1052
Vargish T, Benjamin R, Shenkman L "Deafness from furosemide." Ann Intern Med 72 (1970): 761
Venkateswaran P "Transient deafness from high doses of furosemide." Br Med J 4 (1971): 113
Cooperman LB, Rubin IL "Toxicity of ethacrynic acid and furosemide." Am Heart J 85 (1973): 831-4
Quick CA, Duvall AJ 3d "Early changes in the cochlear duct from ethacrynic acid: an electronmicroscopie evaluation." Laryngoscope 80 (1970): 954-65
"Product Information. Demedex (torsemide)." Boehringer Mannheim, Gaithersburg, MD.
David DS, Hitzig P "Diuretics and ototoxicity." N Engl J Med 284 (1971): 1328-9
"Product Information. Lasix (furosemide)." sanofi-aventis , Bridgewater, NJ.
Merrill JP "Hazards of ethacrynic acid." JAMA 212 (1970): 159
Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995): 1771-80
Pillay VK, Schwartz FD, Aimi K, Kark RM "Transient and permanent deafness following treatment with ethacrynic acid in renal failure." Lancet 1 (1969): 77-9
Matz GJ, Beal DD, Krames L "Ototoxicity of ethacrynic acid. Demonstrated in a human temporal bone." Arch Otolaryngol 90 (1969): 152-5
Arnold W, Nadol JB Jr, Weidauer H "Ultrastructural histopathology in a case of human ototoxicity due to loop diuretics." Acta Otolaryngol (Stockh) 91 (1981): 399-414
Rybak LP "Ototoxicity of loop diuretics." Otolaryngol Clin North Am 26 (1993): 829-44
Homer MJ "Deafness after ethacrynic acid." N Engl J Med 285 (1971): 1152
Boston Collaborative Drug Surveillance Program "Drug-induced deafness." JAMA 224 (1973): 515-6
Matz GJ, Naunton RF "Ototoxic drugs and poor renal function." JAMA 206 (1968): 2119
Blose JS, Adams KF, Patterson JH "Torsemide: a pyridine-sulfonylurea loop diuretic." Ann Pharmacother 29 (1995): 396-402